BofA analyst Derik de Bruin raised the firm’s price target on NeoGenomics to $16 from $15 and keeps a Neutral rating on the shares. NeoGenomics’ Q3 results were ahead of expectations driven by strong trends across the diagnostics industry and better pricing, notes the analyst, who raised the firm’s estimates to reflect the result and commentary. However, while stating that NeoGenomics is making good progress in revamping the business, BofA thinks this is “largely already priced into shares,” the analyst added.
Protect Your Portfolio Against Market Uncertainty
- Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter.
- Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on NEO:
- NeoGenomics price target lowered to $22 from $23 at TD Cowen
- NEO Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- NeoGenomics price target lowered to $16 from $18 at Morgan Stanley
- NeoGenomics announces commercial availability of two new tests
- NeoGenomics price target lowered to $18 from $23 at Piper Sandler